ArticleAngewandte Chemie (International ed. in English)2018
Enzyme-MOF Nanoreactor Activates Nontoxic Paracetamol for Cancer Therapy.
Article in Angewandte Chemie (International ed. in English), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 274 citations in OpenAlex.
- A multienzyme-mimicking nanoplatform induces disulfidptosis/cuproptosis/apoptosis for tumor therapy.National science review · 2026Article
- Potential of Covalent Organic Framework in Pharmacy and Biomedicine: Influence of Structure on Properties and Applications.ChemMedChem · 2026Review
- XOR-mediated tumor-selective nanomaterial therapy: achieving tumor and immune cell dual regulation through intracellular ROS generation.Journal of nanobiotechnology · 2026Article
- A novel sono-activatable nanoreactor induces precision intratumoral juglone generation and caspase 3/GSDME-mediated pyroptosis for treatment of bladder cancer.Journal of nanobiotechnology · 2025Article
- Advances in biomedical applications of Se-based nanozymes.Journal of nanobiotechnology · 2025Review
- Polyphenol-Based Functional Materials: Structural Insights, Composite Strategies, and Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials.Materials today. Bio · 2024Review
- Boosting Enzyme Activity in Enzyme Metal-Organic Framework Composites.Chem & bio engineering · 2024Review
- Nanoparticle-Based Immunotherapy for Reversing T-Cell Exhaustion.International journal of molecular sciences · 2024Review
- Tyrosinases: a family of copper-containing metalloenzymes.Chemtexts · 2024Article
- Hofmeister Effect Promoted the Introduction of Tunable Large Mesopores in MOFs at Low Temperature for Femtomolar ALP Detection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Opportunities and Challenges of Metal-Organic Framework Micro/Nano Reactors for Cascade Reactions.JACS Au · 2023Review
- Synergistic Photodynamic/Antibiotic Therapy with Photosensitive MOF-Based Nanoparticles to Eradicate Bacterial Biofilms.Pharmaceutics · 2023Article
- Bioinspired Framework Catalysts: From Enzyme Immobilization to Biomimetic Catalysis.Chemical reviews · 2023Review
- Metal-Organic Framework (MOF)-A Universal Material for Biomedicine.International journal of molecular sciences · 2023Review
- Utilization of Functionalized Metal-Organic Framework Nanoparticle as Targeted Drug Delivery System for Cancer Therapy.Pharmaceutics · 2023Review
- Porous Framework Materials for Bioimaging and Cancer Therapy.Molecules (Basel, Switzerland) · 2023Review
- Functionalized biological metal-organic framework with nanosized coronal structure and hierarchical wrapping pattern for enhanced targeting therapy.Chemical engineering journal (Lausanne, Switzerland : 1996) · 2023Article
- Photochemically-driven highly efficient intracellular delivery and light/hypoxia programmable triggered cancer photo-chemotherapy.Journal of nanobiotechnology · 2023Article
- Multifunctional metal-organic framework (MOF)-based nanoplatforms for cancer therapy: from single to combination therapy.Theranostics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Prodrug activation, by exogenously administered enzymes, for cancer therapy is an approach to achieve better selectivity and less systemic toxicity than conventional chemotherapy. However, the short half-lives of the activating enzymes in the bloodstream has limited its success. Demonstrated here is that a tyrosinase-MOF nanoreactor activates the prodrug paracetamol in cancer cells in a long-lasting manner. By generating reactive oxygen species (ROS) and depleting glutathione (GSH), the product of the enzymatic conversion of paracetamol is toxic to drug-resistant cancer cells. Tyrosinase-MOF nanoreactors cause significant cell death in the presence of paracetamol for up to three days after being internalized by cells, while free enzymes totally lose activity in a few hours. Thus, enzyme-MOF nanocomposites are envisioned to be novel persistent platforms for various biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.